Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | IL6 | P05231 | 2/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8247680 | 0.89 | TLR8 (0.42) | TLR7IL6ALDH1A1 | |
| SCHEMBL8251906 | 0.86 | AGTR2 (0.39) | S1PR4TLR7AGTR1AGTR2 | |
| SCHEMBL8242374 | 0.86 | AGTR2 (0.39) | TLR7AGTR1AGTR2 | |
| SCHEMBL8242381 | 0.85 | TLR7 (0.35) | S1PR4TLR7IL6AGTR1AGTR2 | |
| SCHEMBL8249741 | 0.85 | F2 (0.36) | S1PR4TLR7IL6AGTR1AGTR2 | |
| SCHEMBL16327722 | 0.85 | ALOX5AP (0.33) | S1PR4PDE10AMAPTAGTR1AGTR2 | |
| SCHEMBL12884189 | 0.85 | CSF1R (0.44) | MAPTKDM4E | |
| SCHEMBL8248706 | 0.84 | HTT (0.46) | AGTR1AGTR2KDM4EALDH1A1 | |
| SCHEMBL8242386 | 0.81 | KDM4E (0.48) | PDE10AMAPTKDM4EPDE2AALDH1A1 | |
| SCHEMBL8251311 | 0.79 | TLR8 (0.42) | S1PR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896450-B1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN R & D IRELAND (IE) | 2012-08-15 | — | — | EP | disclosed |
| US-7884215-B2 | 2-substituted benzimidazoles | JANSSEN SCIENCES IRELAND UC (IE) | 2011-02-08 | — | — | US | disclosed |
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-04-15 | — | — | US | disclosed |
| WO-2006136563-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | HTR4, HRH4, HTR3C | S1PR4 184/4885TLR7 1446/4885PDE10A 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.